NO2903977T3 - - Google Patents

Info

Publication number
NO2903977T3
NO2903977T3 NO13776702A NO13776702A NO2903977T3 NO 2903977 T3 NO2903977 T3 NO 2903977T3 NO 13776702 A NO13776702 A NO 13776702A NO 13776702 A NO13776702 A NO 13776702A NO 2903977 T3 NO2903977 T3 NO 2903977T3
Authority
NO
Norway
Application number
NO13776702A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2903977T3 publication Critical patent/NO2903977T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
NO13776702A 2012-10-08 2013-10-07 NO2903977T3 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012001358 2012-10-08
PCT/US2013/063612 WO2014058747A1 (en) 2012-10-08 2013-10-07 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
NO2903977T3 true NO2903977T3 (zh) 2018-02-17

Family

ID=49354986

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13776702A NO2903977T3 (zh) 2012-10-08 2013-10-07

Country Status (47)

Country Link
US (3) US9469634B2 (zh)
EP (3) EP3656384B1 (zh)
JP (2) JP5877281B2 (zh)
KR (1) KR101696128B1 (zh)
CN (1) CN104822670B (zh)
AP (1) AP2015008355A0 (zh)
AR (1) AR092876A1 (zh)
AU (1) AU2013329552B8 (zh)
BR (1) BR112015007742B8 (zh)
CA (1) CA2887312C (zh)
CL (1) CL2015000880A1 (zh)
CO (1) CO7350655A2 (zh)
CR (1) CR20150183A (zh)
CY (3) CY1119655T1 (zh)
DK (3) DK3656384T3 (zh)
DO (1) DOP2015000082A (zh)
EA (1) EA033436B1 (zh)
EC (1) ECSP15018618A (zh)
ES (3) ES2909190T3 (zh)
GE (1) GEP20186838B (zh)
GT (1) GT201500088A (zh)
HK (2) HK1207369A1 (zh)
HR (3) HRP20220502T1 (zh)
HU (3) HUE058903T2 (zh)
IL (1) IL238090B (zh)
JO (1) JO3470B1 (zh)
LT (3) LT2903977T (zh)
MA (1) MA37959A2 (zh)
MD (1) MD4625C1 (zh)
ME (1) ME02918B (zh)
MX (1) MX355040B (zh)
MY (1) MY192716A (zh)
NI (1) NI201500048A (zh)
NO (1) NO2903977T3 (zh)
NZ (1) NZ706729A (zh)
PE (1) PE20151787A1 (zh)
PH (1) PH12015500764A1 (zh)
PL (3) PL3656384T3 (zh)
PT (3) PT3295942T (zh)
RS (3) RS63112B1 (zh)
SG (1) SG11201502620UA (zh)
SI (3) SI2903977T1 (zh)
TN (1) TN2015000106A1 (zh)
TW (2) TWI538907B (zh)
UA (1) UA114006C2 (zh)
WO (1) WO2014058747A1 (zh)
ZA (1) ZA201503143B (zh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
UY35735A (es) 2013-09-16 2015-04-30 Bayer Pharma AG Trifluorometilpirimidinonas disustituidas y su uso
PT3125894T (pt) * 2014-04-01 2020-11-05 Merck Sharp & Dohme Profármacos de inibidores da transcriptase reversa do vih
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and their uses
CA3032699A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
CA3090652A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
CA3098585A1 (en) 2018-04-30 2019-11-07 Ribon Therapeutics Inc. Pyridazinones as parp7 inhibitors
PE20211774A1 (es) 2018-09-18 2021-09-08 Goldfinch Bio Inc Piridazinonas y sus metodos de uso
EP3898595B1 (en) * 2018-12-18 2024-05-01 Merck Sharp & Dohme LLC Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
BR112021023204A8 (pt) 2019-05-22 2023-04-11 Merck Sharp & Dohme Composto, composição farmacêutica, métodos para tratar infecção por hiv, para induzir dimerização de gag-pol em células infectadas por hiv, para matar seletivamente células expressoras de gag-pol infectadas por hiv e para aumentar a supressão de viremia do hiv, e, uso de um composto
US20240091303A1 (en) * 2019-10-04 2024-03-21 Goldfinch Bio, Inc. Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
AU2020375821A1 (en) 2019-10-30 2022-06-02 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
JP2023543803A (ja) 2020-09-24 2023-10-18 ザ ブロード インスティテュート，インコーポレーテッド プライム編集ガイドｒｎａ、その組成物、及びその使用方法
WO2022150790A2 (en) 2021-01-11 2022-07-14 The Broad Institute, Inc. Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
KR20240029027A (ko) * 2021-07-01 2024-03-05 얀센 파마슈티카 엔브이 5-옥소-피리도[2,3-d]피리다진-6(5H)-일 아세트아미드
EP4381057A2 (en) 2021-08-06 2024-06-12 The Broad Institute Inc. Improved prime editors and methods of use
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
GB202409668D0 (en) 2021-12-03 2024-08-14 Broad Inst Inc Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
WO2024108092A1 (en) 2022-11-17 2024-05-23 The Broad Institute, Inc. Prime editor delivery by aav
WO2024168147A2 (en) 2023-02-09 2024-08-15 The Broad Institute, Inc. Evolved recombinases for editing a genome in combination with prime editing
WO2024206125A1 (en) 2023-03-24 2024-10-03 The Broad Institute, Inc. Use of prime editing for treating sickle cell disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
CA2330304A1 (en) 1998-04-27 1999-11-04 Centre National De La Recherche Scientifique 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
CN100355750C (zh) 2000-09-15 2007-12-19 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
JP5602333B2 (ja) 2003-02-07 2014-10-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ感染の予防のためのピリミジン誘導体
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
RU2344128C2 (ru) 2003-03-24 2009-01-20 Ф.Хоффманн-Ля Рош Аг Бензилпиридазиноны как ингибиторы обратной транскриптазы
CN1934093A (zh) 2004-01-12 2007-03-21 吉里德科学公司 嘧啶基膦酸酯抗病毒化合物和使用方法
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
EP1742908B1 (en) 2004-04-23 2009-11-11 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
CA2592092A1 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
WO2007045572A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
US20080207654A1 (en) 2006-11-24 2008-08-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
RU2010125220A (ru) * 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
EP2231621B1 (en) * 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
PT2924034T (pt) 2010-03-30 2017-01-06 Merck Canada Inc Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico
EP2558093A4 (en) 2010-04-08 2013-10-02 Merck Sharp & Dohme PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
PT3125894T (pt) 2014-04-01 2020-11-05 Merck Sharp & Dohme Profármacos de inibidores da transcriptase reversa do vih

Also Published As

Publication number Publication date
EA033436B1 (ru) 2019-10-31
LT3656384T (lt) 2022-05-10
JP2016128470A (ja) 2016-07-14
PH12015500764B1 (en) 2015-07-27
ES2645638T3 (es) 2017-12-07
AU2013329552B2 (en) 2016-09-15
CY1122585T1 (el) 2021-01-27
HK1207369A1 (zh) 2016-01-29
MD20150047A2 (ro) 2015-08-31
ES2909190T3 (es) 2022-05-05
BR112015007742B8 (pt) 2021-03-23
US9469634B2 (en) 2016-10-18
CL2015000880A1 (es) 2015-08-28
EP3295942A1 (en) 2018-03-21
ME02918B (me) 2018-10-20
DK3295942T3 (da) 2020-02-10
AP2015008355A0 (en) 2015-04-30
JP5877281B2 (ja) 2016-03-02
CA2887312A1 (en) 2014-04-17
IL238090B (en) 2019-02-28
ZA201503143B (en) 2016-06-29
NZ706729A (en) 2018-09-28
US9718819B2 (en) 2017-08-01
ECSP15018618A (es) 2019-06-30
PT3656384T (pt) 2022-03-22
EP3295942B1 (en) 2019-11-20
BR112015007742A2 (pt) 2017-08-08
KR20150065186A (ko) 2015-06-12
PT2903977T (pt) 2017-11-14
RS56543B1 (sr) 2018-02-28
GT201500088A (es) 2017-09-28
MX2015004448A (es) 2016-02-17
MX355040B (es) 2018-03-28
PL3295942T3 (pl) 2020-05-18
LT3295942T (lt) 2020-02-10
TN2015000106A1 (en) 2016-06-29
TW201623256A (zh) 2016-07-01
CO7350655A2 (es) 2015-08-10
JO3470B1 (ar) 2020-07-05
EP3656384B1 (en) 2022-02-23
UA114006C2 (xx) 2017-04-10
CN104822670B (zh) 2018-01-12
GEP20186838B (en) 2018-04-10
LT2903977T (lt) 2017-12-11
PH12015500764A1 (en) 2015-07-27
SI3656384T1 (sl) 2022-05-31
US20160145255A1 (en) 2016-05-26
AR092876A1 (es) 2015-05-06
EA201590674A1 (ru) 2016-02-29
MD4625C1 (ro) 2019-11-30
CY1125202T1 (el) 2024-02-16
CY1119655T1 (el) 2018-04-04
MA37959A2 (fr) 2017-12-29
SI2903977T1 (sl) 2017-12-29
CR20150183A (es) 2015-08-10
ES2770774T3 (es) 2020-07-03
EP2903977B1 (en) 2017-09-20
HUE037231T2 (hu) 2018-08-28
HRP20200158T1 (hr) 2020-08-07
PT3295942T (pt) 2020-02-18
JP2015533123A (ja) 2015-11-19
HK1252786A1 (zh) 2019-05-31
AU2013329552A1 (en) 2015-04-16
MY192716A (en) 2022-09-05
AU2013329552C1 (en) 2016-12-22
RS63112B1 (sr) 2022-05-31
PE20151787A1 (es) 2015-12-03
RS59863B1 (sr) 2020-03-31
BR112015007742B1 (pt) 2021-01-19
US10189831B2 (en) 2019-01-29
AU2013329552B8 (en) 2017-01-12
MD4625B1 (ro) 2019-04-30
TWI598343B (zh) 2017-09-11
PL2903977T3 (pl) 2018-01-31
TW201420576A (zh) 2014-06-01
PL3656384T3 (pl) 2022-04-04
SI3295942T1 (sl) 2020-03-31
CA2887312C (en) 2017-02-28
JP6097422B2 (ja) 2017-03-15
DK2903977T3 (en) 2017-12-04
WO2014058747A1 (en) 2014-04-17
TWI538907B (zh) 2016-06-21
EP2903977A1 (en) 2015-08-12
HRP20171819T1 (hr) 2017-12-29
EP3656384A1 (en) 2020-05-27
NI201500048A (es) 2016-06-29
HUE058903T2 (hu) 2022-09-28
HRP20220502T1 (hr) 2022-05-27
DOP2015000082A (es) 2015-08-16
HUE048670T2 (hu) 2020-08-28
US20140100231A1 (en) 2014-04-10
KR101696128B1 (ko) 2017-01-13
US20170349585A1 (en) 2017-12-07
DK3656384T3 (da) 2022-04-19
SG11201502620UA (en) 2015-05-28
CN104822670A (zh) 2015-08-05

Similar Documents

Publication Publication Date Title
BR112014017635A2 (zh)
BR112014017625A2 (zh)
BR112014019495A2 (zh)
BR112014017659A2 (zh)
BR112014017646A2 (zh)
AR092201A1 (zh)
BR112014017638A2 (zh)
BR112014019474A2 (zh)
BR112014017634A2 (zh)
BR112014017644A2 (zh)
BR112014017728A2 (zh)
BR112014017647A2 (zh)
BR112014017630A2 (zh)
BR112014017652A2 (zh)
BR112014017621A2 (zh)
BR112014017622A2 (zh)
BR112014017627A2 (zh)
BR112014017623A2 (zh)
BR112014017631A2 (zh)
BR112014017641A2 (zh)
BR112014017636A2 (zh)
BR112014017667A2 (zh)
BR112014019437A2 (zh)
BR112014017671A2 (zh)
BR112014017742A2 (zh)